Table 3. Comparison of clinical pathologic features between difference number of MPLN group (≤ 2 and ≥ 3 groups).
| Parameter | Number of MPLN ≤ 2 (n = 31) | Number of MPLN ≥ 3(n = 19) | P-value |
|---|---|---|---|
| Gender | |||
| Male | 9 (29.0%) | 3 (15.8%) | 0.3317 |
| Female | 22 (71.0%) | 16 (84.2%) | |
| Age (years) | 60.58 ± 11.42 | 59.68 ± 8.23 | 0.7674 |
| Pathologic type | |||
| Well-differentiated | 4 (12.9%) | 0 (0%) | 0.8406 |
| Moderately differentiated | 9 (29.0%) | 8 (42.1%) | |
| Poorly differentiated | 12 (38.7%) | 8 (42.1%) | |
| Signet ring cell/mucinous | 6 (19.4%) | 3 (15.8%) | |
| TNM stage | |||
| Stage IB | 6 (19.4%) | 0 (0%) | < 0.0001 |
| Stage II | 13 (41.9%) | 0 (0%) | |
| Stage III | 11 (35.5%) | 14 (73.7%) | |
| Stage IV | 1 (3.2%) | 5 (26.3%) | |
| Surgery type | |||
| Non-R0 | 1 (3.2%) | 10 (52.6%) | < 0.0001 |
| R0 | 30 (96.8%) | 9 (47.4%) | |
| Tumour marker level | |||
| Positive | 10 (32.3%) | 7 (36.8%) | 0.7398 |
| Negative | 21 (67.7%) | 12 (63.2%) | |
| Mean SUVmax of primary | 5.4 (3.9, 8.3) | 7.6 (5.7, 11) | 0.0455 |
| Mean SUVmax of MPLN | 3.6 (2.1, 3.7) | 4.4 (3.5, 6.2) | 0.1019 |